Michael S. Cookson, MD, on what ARASEC adds to the treatment intensification discussion

At the 2026 AUA Annual Meeting, data were presented from the phase 2 ARASEC trial demonstrating that treatment with darolutamide (Nubeqa) plus ADT demonstrated statistically significant improvements in PFS, OS, and PSA response rates compared with ADT alone in US patients with mHSPC. Here, Michael S. Cookson, MD, MMHC, FACS, shares what these data contribute to the conversation about treatment intensification with darolutamide.

For more from AUA 2026, see: https://www.urologytimes.com/conference/aua

Видео Michael S. Cookson, MD, on what ARASEC adds to the treatment intensification discussion канала Urology Times